About this Research Topic
In the field of oncology, the immune system's ability to detect and respond to tumors through the production of autoantibodies has opened up new avenues for cancer diagnosis and treatment. Autoantibodies hold key implications for identifying tumorigenic processes early. As tumors develop and progress, variations in autoantibody presence provide valuable diagnostic and prognostic insights. Due to their stability and persistence, autoantibodies can be reliably detected in serum samples, offering advantages such as being non-invasive, non-degradable, and highly reproducible. Moreover, advancements in antibody detection technologies such as ELISA, SERPA, nano-LC-Q-TOF-MS/MS, and HuProt arrays have triggered further interest in the utilization of autoantibodies as early-screening, diagnostic, and prognostic biomarkers of tumors.
This Research Topic aims to explore tumor-associated autoantibodies and deepen the understanding of autoantibody generation mechanisms, enhance detection methods, and leverage these biomarkers for robust cancer management strategies. Our objective is to fortify the critical adoption of autoantibodies in diagnostic protocols and treatment strategies and amplify their prognostic value across various cancers.
In an effort to expand our knowledge in tumor-specific immune responses and the potential of autoantibodies, we invite submissions on a range of relevant topics, including but not limited to:
o Mechanism of autoantibody production
o Detection of autoantibodies and their combinations in different tumors
o Clinical application of autoantibodies in cancer diagnosis, treatment, and monitoring
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
This Research Topic aims to explore tumor-associated autoantibodies and deepen the understanding of autoantibody generation mechanisms, enhance detection methods, and leverage these biomarkers for robust cancer management strategies. Our objective is to fortify the critical adoption of autoantibodies in diagnostic protocols and treatment strategies and amplify their prognostic value across various cancers.
In an effort to expand our knowledge in tumor-specific immune responses and the potential of autoantibodies, we invite submissions on a range of relevant topics, including but not limited to:
o Mechanism of autoantibody production
o Detection of autoantibodies and their combinations in different tumors
o Clinical application of autoantibodies in cancer diagnosis, treatment, and monitoring
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: autoantibodies and their combinations, tumor, status, prospect
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
